AIDS Treatment News logo      

August 26, 2009

HVTN 505 HIV Vaccine Study Begins Enrolling Volunteers

"The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has opened enrollment in HVTN 505, an exploratory HIV vaccine clinical study examining whether a two-part vaccine regimen can decrease viral load (the amount of HIV in the blood) in study participants who later become infected with HIV. Viral load is an important health indicator in people who are infected with HIV because typically those with less virus remain healthier longer. Further, HIV-infected individuals with reduced levels of virus may be less likely to transmit the virus to other people. ...

HVTN 505 is planned to take place in 12 U.S. cities and is designed to enroll 1,350 HIV-negative men ages 18 to 45 years who have sex with men. Participants must be circumcised and at the time they are enrolling, without Ad5 antibodies resulting from previous exposure to the Ad5 virus. ...

For more information about the HVTN 505 study, see Questions and Answers: The HVTN 505 HIV Vaccine Regimen Study and"

Read more in U.S. NIAID, August 24, 2009.